Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,362 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04566380RecruitingPhase 2
Study for people already taking ONO-4538
This trial is for people who are already being treated with ONO-4538 (either alone or with other treatments) and can continue into an “extension/rollover” study. It checks how well ONO-4538 continues to work and is used safely over more time.
Chiba, ChibaAges 16 years+ - NCT04516447RecruitingPhase 1
Testing a new drug for advanced ovarian cancer
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
Aurora, ColoradoAges 18 years+ - NCT04575935RecruitingPhase 3
Minimally invasive surgery after chemotherapy for advanced ovarian cancer
This trial studies whether doing surgery using smaller incisions after chemotherapy works as well as a more traditional approach for certain people with stage IIIC–IV ovarian, fallopian tube, or primary peritoneal cancer. It may help reduce surgical trauma while aiming for effective tumor removal.
Miami, FloridaAges 18 years+ - NCT04499365RecruitingEarly Phase 1
PET scan for detecting different cancer types
This trial uses a special PET scan to see how well it can find and track different types of cancer. It may help doctors better understand your cancer.
Fuzhou, FujianAges 18–90 - NCT04573140RecruitingPhase 1
RNA vaccine study for newly diagnosed adult and pediatric brain tumors
This Phase 1 trial studies an “RNA-lipid particle” vaccine given after surgery for certain newly diagnosed brain cancers (glioblastoma in adults, high-grade glioma in children/teens). The goal is to see whether the vaccine is safe and can train the immune system to fight the tumor.
Washington D.C., District of ColumbiaAges 4 years+ - NCT04449549RecruitingPhase 2
Nilotinib and paclitaxel for rare solid tumors
This study tests a combination of two drugs, nilotinib and paclitaxel, in people with certain rare cancers that have not responded to standard treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
Bethesda, MarylandAges 18–120 - NCT04434040RecruitingPhase 2
Atezolizumab and sacituzumab to prevent breast cancer return
This trial tests two medicines after surgery and chemotherapy to help lower the risk that triple-negative breast cancer comes back. It’s for people whose cancer still showed “residual” invasive disease after neoadjuvant (before-surgery) chemotherapy, and whose blood test shows traces of tumor DNA.
San Francisco, CaliforniaAges 18 years+ - NCT04479696Recruiting
Video coaching to ease anxiety during brain tumor radiation
This study tests a personalized video meant to reduce stress and anxiety for people getting radiation for brain tumors, and for their caregivers. You and your caregiver would complete short questionnaires before and after using the video support.
Houston, TexasAges 18 years+ - NCT04389281RecruitingPhase 1
X-ray light-activated therapy for hard-to-treat skin tumors
This early-phase study tests an X-ray–activated medicine that is delivered directly into selected tumors to help control cancer that has not responded to standard treatments. If the injected area can be treated safely, it may shrink or slow the tumor and improve local control.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04390737RecruitingPhase 1/Phase 2
Study drug HH2853 for hard-to-treat lymphoma and solid cancers
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT04313140Recruiting
MRI virtual biopsy to predict glioma grade
This study uses special MRI images to estimate the “grade” of a suspected brain tumor (glioma) without taking a tissue sample first. If it works well, it may help doctors better plan care based on imaging.
PoitiersAges 18 years+ - NCT04273061RecruitingPhase 2
Atezolizumab for tumors that look sensitive on DNA/RNA testing
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
Vancouver, British ColumbiaAges 18 years+ - NCT04333706RecruitingPhase 1/Phase 2
Sarilumab plus capecitabine for certain breast cancers
This trial studies whether adding sarilumab to capecitabine can shrink or control metastatic or high-risk breast cancer that lacks HER2 and is either triple-negative or hormone-resistant. It aims to find a safe dose first, then look at how well the treatment works compared with historical results.
Los Angeles, CaliforniaAges 18–99 - NCT04278118Recruiting
Proton radiation study for non-cancer brain tumor types
This trial tests a radiation plan that gives treatment in fewer, larger “fractions” using proton beams (or sometimes photon beams) for certain non-cancer brain tumor types. It aims to see how well this approach works while keeping side effects manageable.
Atlanta, GeorgiaAges 18 years+ - NCT04322734Recruiting
Blood tests study immune and metabolism markers in neurodevelopment
This study looks for biological “signals” in blood—related to the immune system and metabolism—to better understand conditions like autism and other brain or development-related disorders. It may help researchers find markers that could guide future diagnosis or treatment.
Phoenix, ArizonaAges Up to 18 years - NCT04260269Enrolling by invitation
Testing a switch to a different chemotherapy type after heart side effects
This study looks at whether people with solid tumors who develop heart-related side effects during a fluoropyrimidine chemotherapy can safely switch to a different fluoropyrimidine. It aims to see if the new option is feasible to use again when the first one caused cardiotoxicity.
OdenseAges 18 years+ - NCT04317534RecruitingPhase 2
Pembrolizumab after lung cancer surgery versus observation
This trial tests whether pembrolizumab (an immunotherapy drug) given after complete surgery can lower the chance that early-stage lung cancer comes back. You’ll be compared to standard follow-up without extra treatment to see if the drug helps more people stay cancer-free.
Tampa, FloridaAges 18 years+ - NCT04265430RecruitingPhase 4
MRI scans to predict normal-tissue side effects after treatment
This trial uses repeated MRI scans to better predict which patients may develop painful jaw and mouth tissue problems after radiation and/or certain bone or blood-vessel medicines. It may help clinicians spot problems earlier and tailor follow-up care.
Houston, TexasAges 18 years+ - NCT04261192Recruiting
Grow lab models of head and neck cancer to test treatments
This study collects tissue from people with newly diagnosed head and neck squamous cell cancer and grows “mini tumor models” in the lab. The goal is to see how these models respond to new therapies, which may help guide more effective treatment choices in the future.
CaenAges 18 years+ - NCT04235764Recruiting
Testing a new bladder-tumor surgery tool for removed tissue
This trial studies a redesigned surgical instrument used during bladder tumor removal, to see if it can improve how the removed tissue samples are collected. It may help future patients by supporting better study of bladder tissue during cancer care.
Bethesda, MarylandAges 18–120 - NCT04199026Recruiting
Tiny implanted device delivers drugs to sarcoma tumors
This trial tests an implantable device placed during planned surgery to deliver cancer medicines directly to sarcoma tumors and study how they affect the tumors. It may be an option if your sarcoma has come back or spread and surgery is part of standard care.
Houston, TexasAges 10 years+ - NCT04243720Recruiting
Study of immune resistance after immunotherapy
This trial studies why some solid cancers stop responding to immune-based drugs (like anti–PD-1/PD-L1) and what can be done next. You may be eligible if your cancer has progressed after immunotherapy and you can safely undergo a tumor needle biopsy.
Toronto, OntarioAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,362 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.